Citation

  • Authors: Lalonde ME. et al.
  • Year: 2020
  • Journal: J Biotechnol 307 87-97
  • Applications: in vitro / DNA / PEIpro
  • Cell type: CHO
    Description: Chinese hamster ovary cells

Abstract

Alpha-1-antitrypsin (A1AT) is an abundant serum inhibitor of serine proteases. A1AT deficiency is a common genetic disorder which is currently treated with augmentation therapies. These treatments involve weekly injections of patients with purified plasma-derived A1AT. Such therapies can be extremely expensive and rely on plasma donors. Hence, large-scale production of recombinant A1AT (rA1AT) could greatly benefit these patients, as it could decrease the cost of treatments, reduce biosafety concerns and ensure quantitative and qualitative controls of the protein. In this report, we sought to produce

Pubmed